Increased Regulatory T Cells in Different Cancer Types
Author Information
Author(s): Marc Beyer, Sabine Classen, Elmar Endl, Matthias Kochanek, Martin R. Weihrauch, Svenja Debey-Pascher, Percy A. Knolle, Joachim L. Schultze
Primary Institution: University of Bonn
Hypothesis
Is CD127 a better marker for enumerating FOXP3+ regulatory T cells in cancer patients compared to CD25?
Conclusion
The study found that CD4+CD127lowFOXP3+ regulatory T cells are significantly increased in various cancer patients, suggesting that this population is expanded early in tumor development.
Supporting Evidence
- Patients with colorectal cancer, CLL, MGUS, and MM showed significantly increased frequencies of CD127lowFOXP3+ Treg cells compared to healthy individuals.
- Naïve CD4+CD127lowFOXP3+ Treg cells were found to be increased in peripheral blood of cancer patients.
- The study suggests that the expansion of Treg cells is an early event in tumor development.
Takeaway
The study shows that a specific type of immune cell, called regulatory T cells, is more common in people with cancer, which might help doctors understand how cancer grows.
Methodology
The study analyzed blood samples from cancer patients and healthy individuals to assess the frequency of regulatory T cells using flow cytometry.
Potential Biases
Potential bias due to the exploratory nature of the study and the limited number of patients in each cancer subtype.
Limitations
The study did not perform multiplicity adjustment procedures for statistical significance.
Participant Demographics
Included 10 healthy individuals, 7 MGUS, 10 MM, 10 CLL, and 6 CRC patients.
Statistical Information
P-Value
p<0.005
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website